TD Cowen reiterates Boston Scientific stock Buy rating after cyber recovery
Investing.com Canada
TD Cowen has reiterated its Buy rating and $56.00 price target for Boston Scientific (NYSE:BSX) after the medical device company reported substantial recovery from a recent cybersecurity incident. Distribution networks are largely restored, and key product shipments have resumed. Despite the operational recovery, 22 analysts have revised earnings downwards, highlighting ongoing financial impact assessments.
Read the full story
This is a short summary. The complete article is published by Investing.com Canada.
Headline and summary aggregated from public news feeds. For information only — not financial advice.